Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Oncomatryx Biopharma has been awarded €12.5 million in EIC Accelerator funding to advance groundbreaking ADCs for oncology. This funding includes €2.5 million in grants and €10 million in equity investment.

PRIVATEJul 15, 2025•about 1 year ago

Amount Raised

€12.5 Million

Round Type

Venture - Series Unknown

Autonomous Community Of The Basque CountryBiotechnologyHealth CareTherapeutics

Description

Oncomatryx Biopharma, a biotechnology company specializing in Antibody-Drug Conjugates (ADCs) for oncology, received €12.5 million in EIC Accelerator funding. This funding, part of the EU's Horizon Europe program, includes €2.5 million in grants and €10 million in equity investment. A total of 40 companies were selected from 959 applications. This funding will help advance their Phase I clinical trial for difficult-to-treat cancers.

Company Information

Company

Oncomatryx Biopharma

Location

Autonomous Community Of The Basque Country, Spain

About

Oncomatryx Biopharma is a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology. The company's unique ADC platform integrates proprietary novel payloads and advanced conjugation formats, supporting innovative drug development. With a focus on treating hard-to-treat solid tumors, Oncomatryx is recognized as a strategic leader in oncology innovation. The company is advancing its lead ADC candidate, OMTX705, targeting aggressive tumors with high unmet medical needs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Oncomatryx Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Related People

2 contacts
Verified contactsEneko A., Director of Manufacturing hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Oncomatryx Biopharma's next move

See what Strategic adds

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Oncomatryx Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.